Skip to content
value.today

Siga Technologies INC: financial analysis

Ratios worked out from 10 fiscal years of Siga Technologies INC's statements, compared with 665 companies in Biotechnology.

Operating margin, 2025
25.1%
Biotechnology: -60.5%
Return on equity, 2025
11.2%
Biotechnology: -61.0%
Revenue growth, 3 years a year, 2025
-5.1%
Biotechnology: 12.9%
Dividend yield, 2025
18.9%
Biotechnology: 0.4%

Siga Technologies INC scorecard#

Passes 11 of the 23 checks that could be worked out: strongest in financial health (3 of 3), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 19, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' median325.4×P/E 325.4× against Biotechnology's median of 17.5×.
    • ✓Price to book below its peers' median1.1×Price to book 1.1× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median4.3×Price to sales 4.3× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-8.0%Free cash flow is -8.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yield0.3%Earnings yield 0.3% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-31.8%Revenue down 31.8% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-5.1%-5.1% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-5.1%-5.1% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year0.32 vs 0.82Diluted EPS 0.32 in fiscal 2025 against 0.82 the year before (report's currency).
    • ✗Net income higher than five years earlier$23 M$23 M in fiscal 2025 against $56 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability3 of 5
    • ✓Profitable in the newest year$23 MNet income $23 M in fiscal 2025.
    • ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median25.1%25.1% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%11.2%11.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier25.1%25.1% in fiscal 2025 against 38.5% in 2022.
  • Financial health3 of 3
    • ✓Short-term assets cover short-term liabilities11.8×Current ratio 11.83 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone8.20Z-score 8.20 (safe zone) for fiscal 2025.
  • Shareholder returns3 of 4
    • ✓Pays a dividendYesPaid dividends in fiscal 2025.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • ✗Dividends under 75% of net income185.2%Dividends were 185.2% of net income in fiscal 2025.
    • ✓Share count up no more than 2% in a year-0.1%Diluted shares down 0.1% in fiscal 2025.
    • ✓Dividends and buybacks above 3% of the market value18.9%Dividends and buybacks were 18.9% of the market value.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Revenue fell 31.8% against the year before.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

4of 8(1 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profityes
  • Operations brought in cashyes
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio roseyes
  • No new shares issuedno
  • Gross margin roseno
  • Asset turnover roseno

Altman Z-score

A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.

8.20Safe zone(above 2.99, where the formula's author found few failures)
The five parts of the Altman Z-score
PartRatioWeightPoints
Working capital to assets0.89× 1.21.07
Retained earnings to assets-0.20× 1.4-0.27
Operating income to assets0.11× 3.30.36
Market value to liabilities11.03× 0.66.62
Revenue to assets0.43× 10.43

Where the return on equity comes from

The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.

Net margin24.6%Asset turnover0.41×Assets to equity1.11×Return on equity11.2%

Profitability#

Siga Technologies INC: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Gross margin68.6%77.4%87.3%90.6%87.6%74.8%42%
Operating margin25.1%50.5%59.8%38.5%66.7%-60.5%88%
Net margin24.6%42.7%48.7%30.6%52.0%-68.9%86%
Return on equity11.2%28.7%37.1%19.7%45.7%-61.0%91%
Return on assets10.0%23.8%30.3%16.6%38.1%-44.4%93%

Growth#

Siga Technologies INC: growth by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Revenue growth-31.8%-0.9%26.3%-17.1%7.0%15.8%16%
Revenue growth, 3 years a year-5.1%1.2%3.8%60.6%-34.6%12.9%25%
Revenue growth, 5 years a year-5.4%39.0%-21.8%——15.4%14%
Net income growth-60.7%-13.0%100.8%-51.2%23.3%10.1%3%
Earnings per share growth-61.0%-13.7%106.5%-49.5%28.2%7.6%8%

Financial strength#

Siga Technologies INC: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Debt to equity—————0.26×—
Net debt—————$-16 M—
Net debt to EBITDA—————0.05×—
Interest cover—————-22.77×—
Current ratio11.83×9.12×4.42×8.63×6.85×4.39×83%
Equity share of assets90.6%88.3%77.4%87.2%81.2%64.7%87%

Cash#

Siga Technologies INC: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow—————$-40 M—
Free cash flow margin—————-61.5%—
Cash conversion186.7%82.4%139.3%122.7%16.5%72.6%82%
Capital spending share of revenue—————1.7%—

Shareholder returns#

Siga Technologies INC: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Dividend yield18.9%————0.4%100%
Buyback yield0.0%————1.5%0%
Shareholder yield18.9%————1.7%96%
Dividend payout185.2%72.1%47.2%97.2%0.0%18.6%—
Change in share count-0.1%0.3%-2.5%-3.7%-3.8%17.3%94%

Efficiency#

Siga Technologies INC: efficiency by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Asset turnover0.41×0.56×0.62×0.54×0.73×0.26×64%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Net income growth
Net income against the year before. Only when both years were profitable.
Earnings per share growth
Diluted earnings per share against the year before. Only when both were positive.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Net debt to EBITDA
Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Dividend yield
Dividends paid in the fiscal year as a share of today's market value.
Buyback yield
Shares bought back in the fiscal year as a share of today's market value.
Shareholder yield
Dividends plus buybacks as a share of today's market value.
Dividend payout
Dividends paid as a share of net income. Only when the year was profitable.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Siga Technologies INC's statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that Siga Technologies INC is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Siga Technologies INC